Germany Anti-Obesity Drugs Market Insight
Published: 05 June 2026 | Report Format: Electronic (PDF)
Due to increased obesity incidence, GLP-1 therapies, healthcare uptake, and pharmaceutical innovation, the German anti-obesity drugs market is expected to develop at a rate of 11.87%.
Germany Anti-Obesity Drugs Market Insights Forecasts to 2035
- The Germany Anti-Obesity Drugs Market Size Was Estimated USD 423.8 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 11.87% from 2025 to 2035
- The Germany Anti-Obesity Drugs Market Size is Expected to rise around USD 1300.5 Million by 2035
Notable Insights for the Germany Anti-Obesity Drugs Market
- Based on drug class segmentation, demonstrates that demand for semaglutide will propel GLP-1 receptor agonists to the top of the German anti-obesity drug market in 2025. Lipase inhibitors, appetite suppressants, and newly developed multi-receptor medicines will follow.
- Based on type segmentation, demonstrates that in 2025, the German anti-obesity drug market will be dominated by prescription medications due to their great clinical efficacy and regulation, while over-the-counter medications will continue to rise as more cost-effective options.
- The Organization for Economic Co-operation and Development estimates that Germany spends between $43 billion a year nearly 9% of all healthcare spending on obesity-related illnesses, which fuels the market for anti-obesity medications
Download the eBook (ToC)
- Anti-obesity medications are mostly not covered by statutory health insurance, which covers about 74 million people (90%), according to Germany's Social Code (SGB V). This limits their use and slows the market's expansion.
Why Buy This Report
- Get a thorough grasp of market dynamics by learning about market size, past performance, current trends, and long-term projections from 2025 to 2035.
- To enable reliable strategic planning and investment decisions, access well-researched CAGR projections and revenue estimates in USD million and billion, backed by verified techniques.
- Recognize obstacles like high treatment costs and restricted reimbursement regulations, as well as important growth factors like rising obesity prevalence, growing awareness, and demand for cutting-edge medicines.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the Germany anti-obesity drugs market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in Germany Anti-Obesity Drugs Market
- Novo Nordisk
- Eli Lilly
- Boehringer Ingelheim
- Bayer
- Pfizer
- Amgen
- Roche
- Sanofi
- AstraZeneca
- Takeda.
Recent Developments:
- In April 2026, the first daily oral GLP-1 obesity medication, Foundayo (orforglipron), was introduced by Eli Lilly to increase accessibility and convenience for long-term weight control.
- In May 2025, next-generation weight-management pipelines, Novo Nordisk and Septerna developed oral obesity medicines that target GLP-1, GIP, and glucagon receptors.
Market Segmentation:
Germany Anti-Obesity Drugs Market, By Drug Class
- GLP-1 Receptor Agonists
- Lipase Inhibitors
- Emerging Therapies
Germany Anti-Obesity Drugs Market, By Type
- Prescription Drugs (Rx)
- Over the Counter (OTC) Drugs
Germany Anti-Obesity Drugs Market, By Mechanism of Action
- Centrally Acting Drugs
- Peripherally Acting Drugs
Expert Views:
The German anti-obesity medications market offers significant potential for sustained growth, driven by increasing incidences of obesity, advancements in GLP-1 agonists, and increasing drug pipelines. Despite some restrictions posed by reimbursement challenges, ongoing clinical research, oral dosage forms, and multi-receptor agonist medications can be anticipated to help enhance market penetration until 2035.
Author: Govind and Krishna By Spherical Insights and Consulting